Upcoming Events All Events

Latest News

MERCK: Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the results from studies evaluating MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), are scheduled to be presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) taking place July 21 – 24, 2019 in Mexico City.

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A., INC: Konica Minolta Ranked Among World’s Most Elite 501 Managed Service Providers

Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) announced today that the company’s IT Services Division, All Covered (All Covered), has been named as one of the world’s premier managed service providers on the prestigious 12th-annual Channel Futures MSP 501 rankings.

MERCK: Merck to Hold Second-Quarter 2019 Sales and Earnings Conference Call on July 30

Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m.

SOMOS, INC: Somos, Inc. Appoints Telecom Exec Carol Wirsbinski to its Board of Directors

Somos, Inc., a leading registry management and data solutions company, is pleased to announce the appointment of telecommunications executive Carol Wirsbinski to its Board of Directors.

ADP, LLC: ADP to Announce Fourth Quarter Fiscal 2019 Financial Results on July 31, 2019

ADP (Nasdaq: ADP), a leading global provider of Human Capital Management (HCM) solutions, is scheduled to release its financial results for the fourth fiscal quarter ending June 30, 2019 before the opening of the Nasdaq on Wednesday, July 31, 2019.

DAIICHI SANKYO, INC: Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the Ministry of Health, Labor and Welfare (MHLW) of Japan has approved VANFLYTA® (quizartinib), an oral FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), as detected by an MHLW-approved test.

Metro Business Network